title: Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
abstract: Rasburicase has been defined as a potent urolytic agent for management of malignancy-associated hyperuricemia. We reviewed the data of 26 children with malignancy at risk for TLS who received rasburicase for treatment or prophylaxis of acute hyperuricemia, producing a significant decrease in uric acid level in all the patients. Tolerance of treatment was excellent. Rasburicase is a safe, highly and rapidly effective agent in the treatment and prevention of malignancies-associated acute hyperuricemia.
authors.forename: Andrea
authors.initials: A
authors.lastname: Pession
authors.forename: Eveline
authors.initials: E
authors.lastname: Barbieri
authors.forename: Nicola
authors.initials: N
authors.lastname: Santoro
authors.forename: Paolo
authors.initials: P
authors.lastname: Paolucci
authors.forename: Fulvio
authors.initials: F
authors.lastname: Porta
authors.forename: Franco
authors.initials: F
authors.lastname: Locatelli
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000188:drug therapy* / Q000517:prevention & control*; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use*; D015275:Tumor Lysis Syndrome / Q000188:drug therapy / Q000209:etiology; D014503:Urate Oxidase / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; C469709:rasburicase; D014503:Urate Oxidase